Here is the latest CBD news from this week:
- A clinical trial in Poland has found that topical CBD relieves muscle pain.
- Federal agencies have issued pro-hemp banking guidance.
- A major Canadian cannabis company has launched hemp-derived CBD products in the US.
Polish Clinical Trial Finds Topical CBD Relieves Muscle Pain
A randomized, double-blind clinical trial conducted in Poland and published in the Journal of Clinical Medicine has found that transdermal CBD helps relieve muscle pain around the jaw.
Sixty patients with temporomandibular disorders (TMD) participated in the study.
TMD can cause pain in the jaw joint and surrounding muscles, as well as trouble with jaw movement.
The 60 patients were randomly split up into two groups: Group1 and Group2.
Group1 received the transdermal CBD treatment, while Group2 used a placebo.
The participants were told to use their respective treatments twice a day for two weeks.
To analyze the results, researchers measured masseter muscle (cheek muscle) activity and pain intensity.
In the CBD group, researchers found an 11% decrease in the right masseter muscle and 12.6% in the left, compared to 0.23% decrease in the right and 3.3% in the left for the placebo group.
Pain intensity in the CBD group decreased by 70.2%, while the placebo group only had a 9.81% reduction.
The researchers suggested: “there is a need for more research in this field, but CBD, as a substitute for THC, should be considered for the treatment of masticatory muscles in TMD patients.”
Federal Agencies Relax Banking Limitations On Hemp Businesses
Federal agencies have released pro-hemp guidelines, supporting the legalization of hemp and explaining to banks that there is no need to register reports for suspicious activity while working with hemp-related businesses.
Banks were required to submit such reports before the legalization of hemp under the 2018 Farm Bill.
Four federal agencies—The Office of the Comptroller of the Currency, the Financial Crimes Enforcement Network (FinCEN), the Federal Deposit Insurance Corporation, and the Federal Reserve System—along with the Conference of State Bank Supervisors issued a statement earlier this week to clear up the confusion.
A joint press release about the statement says, “The statement highlights that there is no need for banks to submit any suspicious activity reports (SAR) for customers merely because they are involved the cultivation of hemp according to relevant laws and regulations. Banks are expected to follow standard SAR protocols for hemp-related customers, and file a SAR if there is evidence of any suspicious activity.”
The memo also offers details about the interim final rule of USDA on hemp cultivation, which FinCEN will provide more guidance until the proposal of the USDA has been approved.
The revised guidance further underlines the disparities in banking standards for hemp and marijuana companies, according to the US Hemp Roundtable, the most prominent advocacy group in the hemp industry.
Although Roundtable applauded the change, it also notified that further work needs to be done to free up trade for the industry.
Roundtable in an email to its supporters said that it is not required by the bank or financial services companies to collaborate with hemp businesses after today’s guidance, nor is there any particular evidence of hemp-derived CBD or businesses that engage in that trade. Full implementation of the pending SAFE Banking Act is also crucial to further start the hemp and CBD trade to credit card companies and financial institutions.
Canopy Growth Introduced Hemp-Derived CBD In The USA
Canopy development, one of Canada’s most influential cannabis firms, has introduced hemp-derived CBD products.
one of Canada’s most popular cannabis firms has released hemp-derived CBD products in the USA under the brand name “First & Free.”
Canadian producers possess several brands, and have recently released new products for Cannabis 2.0 in Canada.
First & Free is the first brand of the company based in the USA and is shipping products to 31 states in the nation.
All the products from the brands are manufactured using CBD isolate, a hemp extract that eliminates all other cannabinoids from the oil, including THC and plant content.
The company is fully dedicated to creativity and science, according to the First & Free website.
It is claimed by the brand that they have filed 14 investigator-initiated clinical trials planned and ongoing, 54 provisional patents,16 therapeutic trials planned and ongoing, and 2000+ individuals to participate in the research.
First & Free sells softgels, drops, and topicals.
Canopy Growth purchases US cannabis company Acreage assets for $3.4 billion and starts work on a hemp industrial park in New York. So, it has been a busy year for Canopy growth.
